Biogen Idec has signed a definitive agreement to acquire Syntonix Pharmaceuticals for $40 million. Syntonix focuses on discovering and developing long-acting therapeutic products to improve treatment regimens for chronic diseases. Syntonix’s lead product, FIX:Fc, is a proprietary long-acting factor IX product for the treatment of hemophilia B. It has the potential to reduce the frequency of intravenous injections required for disease management. Syntonix expects to file an IND for FIX...